Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2014 June;105(3 Suppl 2) > Minerva Medica 2014 June;105(3 Suppl 2):1-6

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

  PNEUMOLAB PROCEEDINGS Free accessfree

Minerva Medica 2014 June;105(3 Suppl 2):1-6

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Is mild asthma in real life always in the Green Zone?

Patella V. 1, Santus P. 2, Puggioni F. 3, Steinhilber G. 4, Scichilone N. 5

1 Operative Unit of Allergology and Clinic Immunology, Department of Medical Sciences, Battipaglia Hospital, Salerno, Italy; 2 Unit of Rehabilitation Pneumology, Salvatore Maugeri Foundation, Milan University, Milan IRCCS Scientific Institute, Milan, Italy; 3 Operative Unit of Pneumology and Allergology, IRCCS Humanitas Clinical Institute, Rozzano, Milan, Italy; 4 Operative Unit of Respiratory Physiopathology, Division of Pneumology, Spedali Civili di Brescia Hospital, Brescia, Italy; 5 DIBIMIS, Palermo University, Palermo, Italy


PDF


Asthma is a chronic inflammatory disease of the airways that is characterized by variable narrowing of the airways and symptoms of intermittent dyspnea, wheezing, and nighttime or early-morning coughing. Asthma is a major health problem throughout the world, affecting an estimated 315 million persons of all ages. Asthma is clinically heterogeneous, and its pathophysiology is complex. For convenience, asthma action plans are often broken down into three zones, usually based on peak flow meter recordings: green, yellow, and red according to the level of lung function impairment. Recent evidence shows that every asthmatic is potentially at risk for severe exacerbation independently of his/her zone, including the green zone. Furthermore, in real life scenario asthmatic patients can have poor perception of their symptoms or/and overestimate their level of asthma control, and this can obviously confound the clinical picture and favor sudden worsening of symptoms. To understand how to treat these patients, as well as how to assess their future risk, can make a difference in terms of clinical outcomes and prognosis. Following the suggestions and concerns recently published, who recently focused on the clinical management of mild asthma, we aimed at exploring strengthens and gaps in the daily management of the mildest forms of the disease, with a focus on alternative diagnostic and therapeutic strategies in approaching the “green” patient in clinical practice.

top of page